Sandra Misale

6.5k total citations · 1 hit paper
24 papers, 1.1k citations indexed

About

Sandra Misale is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sandra Misale has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Sandra Misale's work include Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Genomics and Diagnostics (7 papers). Sandra Misale is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Genomics and Diagnostics (7 papers). Sandra Misale collaborates with scholars based in United States, Italy and United Kingdom. Sandra Misale's co-authors include Alberto Bardelli, Federica Di Nicolantonio, Andrea Sartore‐Bianchi, Salvatore Siena, Sebastijan Hobor, Alice Lallo, Giulia Siravegna, Luca Lazzari, Sabrina Arena and Emily Crowley and has published in prestigious journals such as Nature, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sandra Misale

21 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

2014 374 citations Sandra Misale, Federica Di Nicolantonio et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Misale United States	9	730	437	361	283	242	24	1.1k
Maria Pia Morelli United States	19	863 1.2×	350 0.8×	449 1.2×	355 1.3×	272 1.1×	70	1.3k
Consalvo Petti Italy	12	614 0.8×	344 0.8×	432 1.2×	137 0.5×	245 1.0×	21	988
Alba Dalmases Spain	12	673 0.9×	484 1.1×	355 1.0×	366 1.3×	275 1.1×	23	1.0k
Omar Kabbarah United States	18	797 1.1×	349 0.8×	620 1.7×	301 1.1×	409 1.7×	42	1.5k
Marisol Huerta Spain	18	610 0.8×	491 1.1×	368 1.0×	398 1.4×	253 1.0×	42	1.2k
Analía Azaro Spain	18	557 0.8×	198 0.5×	569 1.6×	295 1.0×	121 0.5×	56	1.1k
Luca Lazzari Italy	14	433 0.6×	261 0.6×	446 1.2×	190 0.7×	162 0.7×	25	853
Gert Van den Eynden Belgium	17	861 1.2×	381 0.9×	400 1.1×	289 1.0×	77 0.3×	34	1.3k
Emanuele Valtorta Italy	16	661 0.9×	357 0.8×	531 1.5×	331 1.2×	258 1.1×	40	1.2k
Pang‐Dian Fan United States	15	617 0.8×	276 0.6×	596 1.7×	679 2.4×	108 0.4×	25	1.3k

Countries citing papers authored by Sandra Misale

Since Specialization

Citations

This map shows the geographic impact of Sandra Misale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Misale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Misale more than expected).

Fields of papers citing papers by Sandra Misale

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Misale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Misale. The network helps show where Sandra Misale may publish in the future.

Co-authorship network of co-authors of Sandra Misale

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Misale. A scholar is included among the top collaborators of Sandra Misale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Misale. Sandra Misale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Misale, Sandra. (2025). The evolving landscape of RAS-targeted therapies. Nature Cancer. 6(12). 1913–1915.

Jenkins, Brittany D., Wouter R. Karthaus, Jana Lipková, et al.. (2025). Tackling the next decade of cancer research. Trends in cancer. 11(4). 267–273.

Misale, Sandra, et al.. (2024). RAS G12C Inhibitors: Three Birds with One Stone. Cancer Discovery. 14(5). 698–700. 1 indexed citations

Michelini, Flavia, Joshua Z. Drago, Dazhi Liu, et al.. (2024). EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Reports Medicine. 5(11). 101792–101792. 12 indexed citations

Marasco, Michelangelo & Sandra Misale. (2024). The Far Side of Resistance to RAS Inhibitors. Cancer Discovery. 14(11). 2018–2020. 3 indexed citations

Misale, Sandra. (2023). Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Molecular Cancer Research. 21(5_Supplement). IA07–IA07. 1 indexed citations

Achinger-Kawecka, Joanna, Rik G.H. Lindeboom, Sandra Misale, et al.. (2023). The 2023 generation. Nature Cancer. 4(12). 1630–1635. 1 indexed citations

Maria, Ann, HuiYong Zhao, Robert A. Lefkowitz, et al.. (2023). Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers. The Oncologist. 29(1). 15–24. 7 indexed citations

Pilato, Mauro Di, Edward Y. Kim, Bruno L. Cadilha, et al.. (2019). Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature. 570(7759). 112–116. 151 indexed citations

10.

Su, Wenjing, Rona Yaeger, Na Na, et al.. (2019). Abstract LB-265: ARAF activates RAS by antagonizing its interaction with NF1. Cancer Research. 79(13_Supplement). LB–265.

11.

Tong, Jingshan, Dongshi Chen, Sandra Misale, et al.. (2018). Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene. 37(33). 4599–4610. 24 indexed citations

12.

Ahronian, Leanne G., Sandra Misale, Jason Godfrey, et al.. (2017). Abstract 101: Adaptive feedback reactivates MAPK signaling in KRAS-mutant cancers with inhibition of MEK, but not ERK. Cancer Research. 77(13_Supplement). 101–101. 1 indexed citations

13.

Arena, Sabrina, Giulia Siravegna, Benedetta Mussolin, et al.. (2016). MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science Translational Medicine. 8(324). 324ra14–324ra14. 76 indexed citations

14.

Misale, Sandra, Ivana Božić, Jingshan Tong, et al.. (2015). Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications. 6(1). 8305–8305. 91 indexed citations

15.

Hobor, Sebastijan, Beth O. Van Emburgh, Emily Crowley, et al.. (2014). TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells. Clinical Cancer Research. 20(24). 6429–6438. 84 indexed citations

16.

Bardelli, Alberto, Sandra Misale, Sabrina Arena, et al.. (2014). Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients’ avatars.. Journal of Clinical Oncology. 32(15_suppl). 2626–2626. 2 indexed citations

17.

Misale, Sandra, Federica Di Nicolantonio, Andrea Sartore‐Bianchi, Salvatore Siena, & Alberto Bardelli. (2014). Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery. 4(11). 1269–1280. 374 indexed citations breakdown →

18.

Misale, Sandra, Sabrina Arena, Simona Lamba, et al.. (2013). Abstract C94: Heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer are sensitive to concomitant inhibition of EGFR and MEK.. Molecular Cancer Therapeutics. 12(11_Supplement). C94–C94. 1 indexed citations

19.

Demaria, Marco, Sandra Misale, Carlotta Giorgi, et al.. (2012). STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death and Differentiation. 19(8). 1390–1397. 51 indexed citations

20.

Misale, Sandra, et al.. (2012). 166 Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells. European Journal of Cancer. 48. 51–51. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact